Literature DB >> 22489699

Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.

Q Qian, P Zhan, W K Sun, Y Zhang, Y Song, L K Yu.   

Abstract

The mechanisms by which vascular endothelial growth factor (VEGF) and soluble intercellular adhesion molecule-1 (sICAM-1) contribute to lung cancer growth have not been fully elucidated. This study aimed to assess the role of VEGF and sICAM-1 in control of pleural effusions (PE) and survival in patients with primary human lung adenocarcinoma. Using enzyme-linked immunoadsorbent assay, the concentrations of VEGF and sICAM-1 were measured in pleural effusions and serum from a total of 79 lung adenocarcinoma patients with malignant pleural effusions (MPE) and 24 patients with tuberculosis. Data were correlated with the efficacy of MPE control and survival. Compared to patients with tuberculosis, the levels of VEGF and sICAM-1 in both PE and serum were significantly higher in patients with lung adenocarcinoma. Statistically significant correlation was observed between PE VEGF levels and MPE control. PE VEGF≥2760 pg/ml was used as a cut-off point for failure to MPE control (odds ratio=7.06; 95% confidence interval (CI), 2.40-20.78; P<0.001). The median progression-free survival (PFS) from response assessment was 3 months. In a multivariate analysis, PE VEGF (hazard ratio [HR], 1.16; 95% CI, 1.02-1.32), serum sICAM-1 (HR, 1.90; 95% CI, 1.17-3.07) were confirmed as independent prognostic factors for PFS. The levels of VEGF in PE can be used to predict the therapeutic efficacy in the control of MPE and this, together with serum level of sICAM-1 is potential survival factors in lung adenocarcinoma patients with MPE.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22489699     DOI: 10.4149/neo_2012_056

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  6 in total

1.  Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions.

Authors:  Chun-Hua Xu; Ping Zhan; Li-Ke Yu; Xiu-Wei Zhang
Journal:  Tumour Biol       Date:  2013-09-26

Review 2.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

3.  Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis.

Authors:  Amene Saghazadeh; Nima Rezaei
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

Review 4.  Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions.

Authors:  Eleftheria Fafliora; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Physiol Rep       Date:  2016-12

5.  Is analysis of inflammatory biomarkers and lymphocyte subpopulations useful in prediction of tuberculosis treatment outcomes?

Authors:  Greta Musteikienė; Skaidrius Miliauskas; Jurgita Zaveckienė; Daiva Urbonienė; Astra Vitkauskienė; Marius Žemaitis; Albinas Naudžiūnas
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-09-08

6.  Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes.

Authors:  Henry Adekola; Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Zhong Dong; Lami Yeo; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2014-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.